CN105456942A - 一种治疗气滞血瘀型月经过少的药物制剂 - Google Patents
一种治疗气滞血瘀型月经过少的药物制剂 Download PDFInfo
- Publication number
- CN105456942A CN105456942A CN201511022260.XA CN201511022260A CN105456942A CN 105456942 A CN105456942 A CN 105456942A CN 201511022260 A CN201511022260 A CN 201511022260A CN 105456942 A CN105456942 A CN 105456942A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- pharmaceutical preparation
- herba
- caulis spatholobi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 62
- 210000004369 blood Anatomy 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 208000037093 Menstruation Disturbances Diseases 0.000 title claims abstract description 29
- 206010021033 Hypomenorrhoea Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title description 15
- 241000756943 Codonopsis Species 0.000 claims abstract description 27
- 210000000582 semen Anatomy 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 241000628997 Flos Species 0.000 claims description 30
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 27
- 241000729183 Lagopsis Species 0.000 claims description 25
- 238000002481 ethanol extraction Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 235000019640 taste Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 8
- -1 reflux Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 abstract description 29
- 238000011282 treatment Methods 0.000 abstract description 23
- 210000004185 liver Anatomy 0.000 abstract description 21
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 230000001737 promoting effect Effects 0.000 abstract description 19
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 238000005728 strengthening Methods 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241001040831 Carex siderosticta Species 0.000 abstract 1
- 241000608174 Gymnadenia Species 0.000 abstract 1
- 235000004185 Hyptis suaveolens Nutrition 0.000 abstract 1
- 244000137850 Marrubium vulgare Species 0.000 abstract 1
- 235000005321 Marrubium vulgare Nutrition 0.000 abstract 1
- 206010027339 Menstruation irregular Diseases 0.000 abstract 1
- 235000004789 Rosa xanthina Nutrition 0.000 abstract 1
- 241000109329 Rosa xanthina Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 208000019255 Menstrual disease Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 8
- 230000002175 menstrual effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000009530 yishen Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000545 luteal phase defect Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/264—Aristolochia (Dutchman's pipe)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药领域,涉及治疗月经不调的药物,尤其涉及一种治疗气滞血瘀型月经过少的药物制剂。该药物制剂由香附、玫瑰花、崖棕根、手掌参、黄精、夏至草、党参、白术、姜黄、菟丝子、鸡血藤、天仙藤为药用原料制成,方中各原料的重量份配比如下:香附11-18份、玫瑰花10-20份、崖棕根10-20份、手掌参15-25份、黄精8-13份、夏至草5-15份、党参8-18份、白术5-15份、姜黄2-8份、菟丝子10-18份、鸡血藤10-20份、天仙藤8-18份。其以疏肝健脾为主,辅以补肾,有活血化瘀,通经活络,填精养阴,理气和血之功,针对气滞血瘀引起的月经过少患者疗效显著。
Description
技术领域
本发明属于中药领域,涉及治疗月经不调的药物,尤其涉及一种治疗气滞血瘀型月经过少的药物制剂。
背景技术
月经过少是指月经周期正常,月经量明显减少,或行经时间不足2天,甚或点滴即净者。月经过少是现代育龄期妇女的常见病,一般认为经量少于20ml为月经过少的诊断分界线,若不及时治疗,可发展成闭经、不孕。
随着社会的发展变化,越来越多内外因素能导致女性月经过少。西方医学认为月经过少为一临床症状,对其研究较少,治疗上以病因治疗为主,往往效果不甚明显。
当代中医学家根据古籍记载及临床经验,认为月经量少的病因病机有虚有实,虚者以血海亏损、精血衰少为主,实者以淤血内阻、痰湿阻滞为主,可分为肾虚、血虚、血瘀、痰湿、肝郁气滞等症型。月经过少在临床上多以虚证和虚实夹杂多见,常见有肾虚血瘀、肝肾不足、肾虚肝郁、气滞血瘀等证型。近年来中医各种疗法在改善患者症状和体征,避免西药治疗的不良反应等方面取得较好疗效。
发明内容
祖国医学认为,气是构成人体和维持人体生命活动的最基本物质,气是生命活动的根源,全身各个器官的功能活动,都是在“气”的充斥下产生其生理功能,脏腑功能的正常运行及气血的和调,才能经候如常,气滞血瘀,阻滞胞脉,使血行不畅,故月经量少。
发明人结合古今先贤的理论与自己的临床经验,将现代生理病理与中医病因病机、辨证与辨病有机结合起来,提供了一种治疗气滞血瘀型月经过少的药物制剂,其以疏肝健脾为主,辅以补肾,有活血化瘀,通经活络,填精养阴,理气和血之功,针对气滞血瘀引起的月经过少患者疗效显著。
本发明采用的技术方案如下:
一种治疗气滞血瘀型月经过少的药物制剂,其由香附、玫瑰花、崖棕根、手掌参、黄精、夏至草、党参、白术、姜黄、菟丝子、鸡血藤、天仙藤为药用原料制成,方中各原料的重量份配比如下:
香附11-18份、玫瑰花10-20份、崖棕根10-20份、手掌参15-25份、黄精8-13份、夏至草5-15份、党参8-18份、白术5-15份、姜黄2-8份、菟丝子10-18份、鸡血藤10-20份、天仙藤8-18份。
进一步优选地,一种治疗气滞血瘀型月经过少的药物制剂,其由以下重量份配比的药用原料制成:
香附13-17份、玫瑰花10-15份、崖棕根12-17份、手掌参18-23份、黄精8-13份、夏至草7-12份、党参9-14份、白术7-12份、姜黄3-6份、菟丝子13-18份、鸡血藤13-18份、天仙藤10-15份。
进一步优选地,一种治疗气滞血瘀型月经过少的药物制剂,其由以下重量份配比的药用原料制成:
香附15份、玫瑰花12份、崖棕根12份、手掌参20份、黄精10份、夏至草8份、党参11份、白术9份、姜黄5份、菟丝子15份、鸡血藤15份、天仙藤15份。
本发明方解,方中:香附辛能散,微苦能降,微甘能和,善疏肝行气;玫瑰花行气解郁,和血散瘀,二药伍用理气解郁,和血散瘀,以疏肝健脾为主,为君药。崖棕根甘辛温,善益气养血,活血调经;黄精补气养阴,健脾,润肺,益肾,平补气血而润;鸡血藤苦甘温,补血,活血,通络;手掌参甘平,益肾健脾,理气和血,四药伍用补血益气,活血通络,养血调经为臣药。姜黄苦辛性温,破血行气,通经;夏至草辛苦寒,养血活血,清热散瘀;助君药活血化瘀;党参补中益气,健脾益肺;白术健脾益气,燥湿利水,二药健脾助运,菟丝子平补肝肾而不燥;天仙藤行气活血,具为佐药。
本方所用各药材的药理活性研究现状如下:
香附:【性味】辛、微苦、微甘,平。【归经】归肝、脾、三焦经。【功能主治】行气解郁,调经止痛。用于肝郁气滞,胸、胁、脘腹胀痛,消化不良,胸脘痞闷,寒疝腹痛,乳房胀痛,月经不调,经闭痛经。
玫瑰花:【性味】甘、微苦,温。【归经】归肝、脾经。【功能主治】行气解郁,和血,止痛。用于肝胃气痛,食少呕恶,月经不调,跌扑伤痛。【功能主治】理气解郁,和血散瘀。治肝胃气痛,新久风痹,吐血咯血,月经不调,赤白带下,痢疾,乳痈,肿毒。
崖棕根:【性味】味甘;辛;性温。【归经】肺;肝;肾经。【功能主治】益气养血;活血调经。主气血虚弱;倦怠无力;心悸失眠;月经不调;经闭【用法用量】内服:煎汤,【临床应用】治妇人血气,并五劳七伤。崖棕根、半天回、鸡翁藤、野兰根等四味,净洗焙干,去粗皮,等分,捣罗,温酒调服二钱匕。
手掌参:【性味】甘;平。【归经】肺;脾;胃经。【功能主治】止咳平喘;益肾健脾;理气和血;止痛。主肺虚咳喘;虚劳消瘦;神经衰弱;肾虚腰腿酸软;阳痿;滑精;尿频;慢性肝炎;久泻;失血;带下;乳少;跌打损伤。.《陕西中草药》:滋补强壮,补脾润肺,安神镇惊,益气止痛。治身体虚弱,神经衰弱,劳伤,咳嗽,气喘。
黄精:【性味】甘,平。【归经】归脾、肺、肾经。【功能主治】补气养阴,健脾,润肺,益肾。用于脾胃虚弱,体倦乏力,口干食少,肺虚燥咳,精血不足,内热消渴。
夏至草:性味】味辛;微苦;性寒。【归经】归肝经。【功能主治】养血活血;清热利湿。主月经不调;产后瘀滞腹痛;血虚头昏;半射不遂;跌打损伤;水肿;小便不利;目赤肿痛;疮痈;冻疮;牙痛;皮疹瘙痒。
党参:【性味】甘,平。【归经】归脾、肺经。【功能主治】补中益气,健脾益肺。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴。《本草正义》:“党参力能补脾养胃,润肺生津,健运中气,本与人参不甚相远。其尤可贵者,则健脾运而不燥,滋胃阴而不湿,润肺而不犯寒凉,养血而不偏滋腻,鼓舞清阳,振动中气而无刚燥之弊。”
白术:【性味】苦、甘,温。【归经】归脾、胃经。【功能主治】健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。
菟丝子:【性味】甘,温。【归经】归肝、肾、脾经。【功能主治】滋补肝肾,固精缩尿,安胎,明目,止泻。用于阳痿遗精,尿有余沥,遗尿尿频,腰膝酸软,目昏耳鸣,肾虚胎漏,胎动不安,脾肾虚泻;外治白癜风。本品性柔润,平补肝肾而不燥。
鸡血藤:【性味】苦、甘,温。【归经】归肝、肾经。【功能主治】补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛。
天仙藤:【性味】苦;温。【归经】肝;脾;肾经。【功能主治】行气活血;利水消肿;解毒。主胃痛;疝气痛;妊娠水肿;产后血气腹痛;蛇虫咬伤。
为了更好地表达本发明的药物制剂,本发明药物制剂是由香附、玫瑰花、崖棕根、手掌参、黄精、夏至草、党参、白术、姜黄、菟丝子、鸡血藤、天仙藤或其水或其有机溶剂提取物为活性成分,可加入药物可接受的载体,依照制剂学常规技术制成。
本发明的药物制剂可以是任何可药用的剂型,这些剂型包括:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂。
上述所述的药物制剂优选的是口服剂型,如:软胶囊剂、胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂;进一步优选为片剂、胶囊剂或颗粒剂;最优选为胶囊剂。
本发明的药物制剂,在制备成药剂时可选择性的加入适合的药物可接受的载体,所述药物可接受的载体选自:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、土温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的发明人在研究中还发现,通过优化制备方法,能够在保持有效药物的情况下,去除杂质或无药效的部分,减少杂质对治疗效果的干扰,使得该药物制剂更加有效,并且由此减少药物的用量。因此,本发明还提供了一种治疗气滞血瘀型月经过少的药物制剂的制备方法,该方法包括以下步骤:
(1)香附、玫瑰花、姜黄、鸡血藤、天仙藤,加入2-10倍量75%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味得乙醇提取物清膏,备用;
(2)将香附、玫瑰花、姜黄、鸡血藤、天仙藤乙醇提取后滤渣与崖棕根、手掌参、黄精、夏至草、党参、白术、菟丝子合并,加3-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.07(60℃测),放置至室温,加入乙醇使含醇量达35%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,与上述乙醇提取物清膏合并,混合均匀,减压干燥至干,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成本发明的药物制剂。
本发明的制剂在使用时根据病人的情况确定用法用量。本发明的制剂在使用时根据病人的情况确定用法用量,可每日服1-3次,每次1-20剂,如:1-20袋或粒或片。
本发明抓住疾病本质进行针对治疗,所谓“有是证用是药”,从而保证了良好的临床疗效,并通过临床观察试验进一步说明了本发明的有益效果,详述如下。
1资料与方法
1.1一般资料:观察2013年10月至2014年8月就诊于我院妇科门诊确诊为月经量少证属气滞血瘀证的患者96例,随机分为观察组与对照组进行观察,每组48例。观察组年龄18-31岁,平均年龄22.2±3.1岁,对照组年龄18-32岁,平均21.9±3.3岁;观察组病程最长1.8年,最短4个月,平均1.05±0.56年,对照组病程最长1.7年,最短3个月,平均1.16±0.64年,两组一般资料比较无统计学差异(P>0.05),具有可比性。
1.2诊断标准:按照张玉珍等编著《中医妇科学》和中华人民共和国卫生部2002年颁布的《中药新药治疗月经不调的临床研究指导原则》的月经过少的诊断标准。
月经过少:月经过少是指月经周期正常,月经血量较常量明显减少,甚至点滴即净,或经行时间不足2天,经量亦少的月经病。
中医辨证标准:参考中华人民共和国卫生部2002年颁布的《中药新药治疗月经不调的临床研究指导原则》的有关内容,制定气滞血瘀证:
经行涩少,淋漓不畅,色黯红有块,小腹疼痛拒按、痛处不移,或伴胸胁胀满,或口干不欲饮;舌质紫黯,或有瘀斑瘀点,脉弦或涩。
1.3排除标准:有内分泌异常、黄体功能不全、宫腔器质性病变者;有甲状腺功能亢进、结核、严重贫血等慢性消耗性疾病者;3个月内有口服激素、使用避孕药者;服药过程中出现不良反应者;未按规定用药,无法判断疗效或资料不全等影响疗效或统计处理者。
1.4治疗方法:
观察组:月经第5天开始使用本发明实施例1制备的胶囊剂,每日2-4粒,服用至月经来潮时停服,以3个月为一个疗程,连续服用3个月。
对照组:使用西药行人工周期雌孕激素序贯疗法,从月经第5天开始,患者口服补佳乐1mg,1次/d,连服21d;自第15天开始,加用黄体酮胶丸100mg,2次/d,服至第21天与补佳乐同时停药。连续治疗3个月经周期。
1.5治疗前后观察指标:
1.5.1治疗前后患者的相关症状。
1.5.2用药期间药物不良反应的观察:观察用药期间有无出现不良反应并记录,如胃肠道不适、过敏反应、阴道出血时间延长等。
1.5.3随访性观测:治疗结束后第三次月经来潮后随访,记录相关症状观察。
1.6疗效标准:根据《中药新药治疗月经不调的临床研究指导原则》,拟定以下疗效标准:治愈:治疗后月经周期、经量恢复正常,其他症状消失,停药3个月经周期未复发者。显效:月经量增加1/3,其他症状消失减轻,积分较治疗前减少70%,停药3个月经周期无复发者。有效:治疗后月经周期、经量、经期较治疗前改善,其他症状较治疗前减轻,积分较治前减少30~69%。无效:治疗后月经周期、经量及经期无改善,积分较治疗前减少30%以下。
1.7统计学方法:采用SPSS16.0统计软件进行计算。各数值以表示,计量资料采用t检验,计数资料采用χ2检验,以P<0.05为差异有统计学意义。
2结果
2.1两组患者疗效比较:上述96例患者治疗后,观察组治愈18例,显效22例,有效8例,无效0例,显效率83.3%,总有效率100%;对照组治愈8例,显效16例,有效16例,无效8例,显效率50.0%,总有效率83.3%,观察组与对照组显效率、总有效率比较,差异有统计学意义(P<0.05),说明观察组较对照组可以明显的提高月经过少的临床治愈率及显效率。见表1。
表1两组患者疗效比较(n%,例)
注:与对照组比较,*P<0.05。
2.2用药期间药物不良反应的观察:观察组患者用药期间有无患者出现轻度胃肠道反应。对照组患者用药期间有17例患者出现轻度胃肠道反应,如恶心、呕吐、上腹隐痛;有5例患者出现不规则阴道流血,观察组与对照组比较,差异有统计学意义,观察组不良反应更少,患者依从性更好。
治疗结果显示:观察组较对照组可以明显提高月经过少的临床治愈率及显效率;可明显的改善患者的临床症状,具有更好的远期疗效,并且患者的临床症状不易复发,不良反应少,是一种安全有效的药物制剂,为中医药治疗月经过少提供新的方法。
总之,与现有技术相比,本发明具有以下有益效果:
本发明药物制剂所选药材配伍相宜,符合中医药学和现代医药学理论,立法全面,用药周到,其以疏肝健脾为主,辅以补肾,重视肝肾脾胃等脏腑的调节,诸药相伍,共奏疏肝健脾、活血化瘀,通经活络,填精养阴,理气和血之效。通补相宜、动静结合,从根本上治疗月经量少,疗效显著,患者依从性较好,服用方便,可有效地减轻病者负担和痛苦,能够达到标本兼治的目的,而被广大患者认可。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1
处方:香附15份、玫瑰花12份、崖棕根12份、手掌参20份、黄精10份、夏至草8份、党参11份、白术9份、姜黄5份、菟丝子15份、鸡血藤15份、天仙藤15份。
制备方法:
(1)香附、玫瑰花、姜黄、鸡血藤、天仙藤,加入2-10倍量75%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味得乙醇提取物清膏,备用;
(2)将香附、玫瑰花、姜黄、鸡血藤、天仙藤乙醇提取后滤渣与崖棕根、手掌参、黄精、夏至草、党参、白术、菟丝子合并,加3-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.07(60℃测),放置至室温,加入乙醇使含醇量达35%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,与上述乙醇提取物清膏合并,混合均匀,减压干燥至干,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成胶囊剂。每粒含生药2.2g。
实施例2
处方:香附12份、玫瑰花10份、崖棕根15份、手掌参22份、黄精12份、夏至草10份、党参14份、白术10份、姜黄3份、菟丝子15份、鸡血藤13份、天仙藤10份。
制备方法:参照实施例1。
实施例3
处方:香附15份、玫瑰花15份、崖棕根15份、手掌参15份、黄精12份、夏至草15份、党参15份、白术10份、姜黄2份、菟丝子10份、鸡血藤20份、天仙藤8份。
制备方法:参照实施例1。
实施例4
处方:香附13份、玫瑰花10份、崖棕根17份、手掌参22份、黄精8份、夏至草10份、党参12份、白术8份、姜黄5份、菟丝子18份、鸡血藤16份、天仙藤10份。
制备方法:参照实施例1。
实施例5
处方:香附17份、玫瑰花15份、崖棕根16份、手掌参18份、黄精12份、夏至草10份、党参16份、白术8份、姜黄8份、菟丝子15份、鸡血藤18份、天仙藤12份。
制备方法:参照实施例1。
实施例6
处方:香附14份、玫瑰花15份、崖棕根15份、手掌参20份、黄精9份、夏至草10份、党参16份、白术8份、姜黄7份、菟丝子18份、鸡血藤10份、天仙藤15份。
制备方法:参照实施例1。
实施例7
处方:香附12份、玫瑰花18份、崖棕根18份、手掌参25份、黄精12份、夏至草5份、党参15份、白术10份、姜黄8份、菟丝子16份、鸡血藤18份、天仙藤10份。
制备方法:参照实施例1。
实施例8
处方:香附15份、玫瑰花12份、崖棕根12份、手掌参20份、黄精10份、夏至草8份、党参11份、白术9份、姜黄5份、菟丝子15份、鸡血藤15份、天仙藤15份。
制备方法:
(1)香附、玫瑰花、姜黄、鸡血藤、天仙藤,加入2-10倍量75%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味得乙醇提取物清膏,备用;
(2)将香附、玫瑰花、姜黄、鸡血藤、天仙藤乙醇提取后滤渣与崖棕根、手掌参、黄精、夏至草、党参、白术、菟丝子合并,加3-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.07(60℃测),放置至室温,加入乙醇使含醇量达35%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,与上述乙醇提取物清膏合并,混合均匀,减压干燥至干,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成片剂。
实施例9
处方:香附15份、玫瑰花12份、崖棕根12份、手掌参20份、黄精10份、夏至草8份、党参11份、白术9份、姜黄5份、菟丝子15份、鸡血藤15份、天仙藤15份。
制备方法:
(1)香附、玫瑰花、姜黄、鸡血藤、天仙藤,加入2-10倍量75%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味得乙醇提取物清膏,备用;
(2)将香附、玫瑰花、姜黄、鸡血藤、天仙藤乙醇提取后滤渣与崖棕根、手掌参、黄精、夏至草、党参、白术、菟丝子合并,加3-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.07(60℃测),放置至室温,加入乙醇使含醇量达35%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,与上述乙醇提取物清膏合并,混合均匀,减压干燥至干,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成颗粒剂。
Claims (9)
1.一种治疗气滞血瘀型月经过少的药物制剂,其特征在于由香附、玫瑰花、崖棕根、手掌参、黄精、夏至草、党参、白术、姜黄、菟丝子、鸡血藤、天仙藤为药用原料制成。
2.如权利要求1所述的药物制剂,其特征在于由以下重量份配比的药用原料制成:
香附11-18份、玫瑰花10-20份、崖棕根10-20份、手掌参15-25份、黄精8-13份、夏至草5-15份、党参8-18份、白术5-15份、姜黄2-8份、菟丝子10-18份、鸡血藤10-20份、天仙藤8-18份。
3.如权利要求2所述的药物制剂,其特征在于由以下重量份配比的药用原料制成:
香附13-17份、玫瑰花10-15份、崖棕根12-17份、手掌参18-23份、黄精8-13份、夏至草7-12份、党参9-14份、白术7-12份、姜黄3-6份、菟丝子13-18份、鸡血藤13-18份、天仙藤10-15份。
4.如权利要求3所述的药物制剂,其特征在于由以下重量份配比的药用原料制成:
香附15份、玫瑰花12份、崖棕根12份、手掌参20份、黄精10份、夏至草8份、党参11份、白术9份、姜黄5份、菟丝子15份、鸡血藤15份、天仙藤15份。
5.如权利要求1-4所述的药物制剂,其特征在于制备方法包括以下步骤:
(1)香附、玫瑰花、姜黄、鸡血藤、天仙藤,加入2-10倍量75%乙醇,回流提取两次,每次1-3小时,滤过,合并两次滤液,减压回收乙醇至无醇味得乙醇提取物清膏,备用;
(2)将香附、玫瑰花、姜黄、鸡血藤、天仙藤乙醇提取后滤渣与崖棕根、手掌参、黄精、夏至草、党参、白术、菟丝子合并,加3-10倍量水,煎煮提取3次,每次1-3小时,合并滤液,滤过,浓缩至相对密度1.05-1.07(60℃测),放置至室温,加入乙醇使含醇量达35%,搅匀,-5-0℃冷藏12小时,滤过,滤液减压回收乙醇至无醇味,与上述乙醇提取物清膏合并,混合均匀,减压干燥至干,得到药物活性成分;该成分单独或与药物可接受的载体混合,依照制剂学常规技术制成本发明的药物制剂。
6.如权利要求1-4所述的药物制剂,其特征在于所述药物制剂优选的是口服剂型。
7.如权利要求6所述的药物制剂,其特征在于所述口服剂型优选为软胶囊剂、胶囊剂、片剂、口服液、颗粒剂、丸剂、散剂、丹剂、膏剂。
8.如权利要求7所述的药物制剂,其特征在于所述口服剂型优选为胶囊剂、片剂或颗粒剂。
9.如权利要求8所述的药物制剂,其特征在于所述口服剂型优选为胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511022260.XA CN105456942A (zh) | 2015-12-30 | 2015-12-30 | 一种治疗气滞血瘀型月经过少的药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201511022260.XA CN105456942A (zh) | 2015-12-30 | 2015-12-30 | 一种治疗气滞血瘀型月经过少的药物制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105456942A true CN105456942A (zh) | 2016-04-06 |
Family
ID=55595391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201511022260.XA Pending CN105456942A (zh) | 2015-12-30 | 2015-12-30 | 一种治疗气滞血瘀型月经过少的药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105456942A (zh) |
-
2015
- 2015-12-30 CN CN201511022260.XA patent/CN105456942A/zh active Pending
Non-Patent Citations (1)
Title |
---|
何任: "《跟名师学临床系列丛书 何任》", 30 June 2010, 中国医药科技出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101953936B (zh) | 一种治疗免疫性血小板减少性紫癜的中药制剂及其制备方法 | |
CN105267543A (zh) | 一种治疗气滞血瘀型原发性痛经伴黄褐斑的中药制剂 | |
CN102579975B (zh) | 一种治疗银屑病的中药混合物 | |
CN105641445A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物及制备方法 | |
CN106177268A (zh) | 一种治疗阳痿的中药组合物及其制备方法 | |
CN105456942A (zh) | 一种治疗气滞血瘀型月经过少的药物制剂 | |
CN102552824B (zh) | 用于治疗银屑病的中成药 | |
CN105288372A (zh) | 一种治疗原发性痛经伴痤疮的药物制剂 | |
CN105535199A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物制剂 | |
CN105687539A (zh) | 一种治疗封闭抗体低下型复发性流产的药物制剂 | |
CN106166251A (zh) | 一种用于治疗哮喘的中药制剂及其制备方法 | |
CN105395768A (zh) | 一种治疗气血两虚型月经量少的药物组合物 | |
CN105327067A (zh) | 一种治疗流产术后内分泌正常型月经过少的中药制剂 | |
CN105597020A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
CN105362698A (zh) | 一种治疗人工流产术后月经量少的药物制剂 | |
CN105362963A (zh) | 一种治疗寒凝血瘀型月经量少的药物制剂 | |
CN105343413A (zh) | 一种治疗肝郁气滞型月经过少的药物制剂 | |
CN109806306A (zh) | 一种治疗痛经的颗粒冲剂及其制备方法 | |
CN105497400A (zh) | 一种治疗肾虚痰湿型月经过少的药物组合物 | |
CN105288495A (zh) | 一种治疗原发性痛经伴痤疮的药物组合物及其制备方法 | |
CN105362695A (zh) | 一种治疗月经过少伴痤疮的药物制剂及其制备方法 | |
CN105434883A (zh) | 一种治疗肝郁血虚型月经过少的药物制剂 | |
CN105833031A (zh) | 一种用于甲状腺癌术后心肾阴虚证的药物组合物 | |
CN108653526A (zh) | 中医治疗重症肌无力的药方 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160406 |